HOWL
Werewolf Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$0.37+0.00%
Price as of Jul 20, 2026
HOWL financials
Werewolf Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $1.9M | $19.9M | $16.4M |
| Cost of revenue | $1.6M | $1.8M | $1.8M | $2.5M |
| Gross profit | -$1.6M | $71.0K | $18.2M | $13.9M |
| Operating expenses | $59.0M | $73.7M | $58.7M | $69.9M |
| Operating income | -$60.7M | -$73.6M | -$40.5M | -$56.1M |
| Net income | -$60.8M | -$70.5M | -$37.4M | -$53.8M |
| EBITDA | -$53.9M | -$64.0M | -$32.5M | -$51.3M |
| Basic EPS | $-1.32 | $-1.63 | $-1.05 | $-1.86 |
| Diluted EPS | $-1.33 | $-1.63 | $-1.05 | $-1.86 |
| Balance sheet | ||||
| Cash & equivalents | $58.0M | $111.0M | $134.3M | $129.3M |
| Total assets | $69.4M | $126.9M | $174.8M | $160.2M |
| Total liabilities | $44.6M | $53.5M | $63.5M | $37.9M |
| Stockholders’ equity | $24.8M | $73.4M | $111.4M | $122.3M |
| Total debt | $9.4M | $37.1M | $51.9M | $14.7M |
| Net debt | -$48.5M | -$73.9M | -$82.4M | -$114.6M |
| Cash flow | ||||
| Operating cash flow | -$60.3M | -$56.2M | -$32.6M | -$40.6M |
| Capital expenditure | $0.00 | -$254.0K | -$769.0K | -$3.6M |
| Free cash flow | -$60.3M | -$56.4M | -$33.4M | -$44.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |